355 related articles for article (PubMed ID: 16370929)
1. Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
Martinez A; Castro A
Expert Opin Investig Drugs; 2006 Jan; 15(1):1-12. PubMed ID: 16370929
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of cholinesterase inhibitors in Alzheimer's disease.
Håkansson L
Acta Neurol Scand Suppl; 1993; 149():7-9. PubMed ID: 7907455
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease.
Lahiri DK; Alley GM; Tweedie D; Chen D; Greig NH
Neuromolecular Med; 2007; 9(2):157-68. PubMed ID: 17627035
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Potential of Multifunctional Tacrine Analogues.
Przybyłowska M; Kowalski S; Dzierzbicka K; Inkielewicz-Stepniak I
Curr Neuropharmacol; 2019; 17(5):472-490. PubMed ID: 29651948
[TBL] [Abstract][Full Text] [Related]
6. 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
Schott Y; Decker M; Rommelspacher H; Lehmann J
Bioorg Med Chem Lett; 2006 Nov; 16(22):5840-3. PubMed ID: 16945529
[TBL] [Abstract][Full Text] [Related]
7. An update on the pharmacology of galantamine.
Villarroya M; García AG; Marco-Contelles J; López MG
Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
[TBL] [Abstract][Full Text] [Related]
8. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
Musiał A; Bajda M; Malawska B
Curr Med Chem; 2007; 14(25):2654-79. PubMed ID: 17979717
[TBL] [Abstract][Full Text] [Related]
9. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Rakonczay Z
Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
[TBL] [Abstract][Full Text] [Related]
10. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent.
Greig NH; Utsuki T; Ingram DK; Wang Y; Pepeu G; Scali C; Yu QS; Mamczarz J; Holloway HW; Giordano T; Chen D; Furukawa K; Sambamurti K; Brossi A; Lahiri DK
Proc Natl Acad Sci U S A; 2005 Nov; 102(47):17213-8. PubMed ID: 16275899
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterases and the fine line between poison and remedy.
Pope CN; Brimijoin S
Biochem Pharmacol; 2018 Jul; 153():205-216. PubMed ID: 29409903
[TBL] [Abstract][Full Text] [Related]
12. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Liston DR; Nielsen JA; Villalobos A; Chapin D; Jones SB; Hubbard ST; Shalaby IA; Ramirez A; Nason D; White WF
Eur J Pharmacol; 2004 Feb; 486(1):9-17. PubMed ID: 14751402
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Darreh-Shori T; Hosseini SM; Nordberg A
J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
16. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Imbimbo BP
CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of imperatorin analogs and their evaluation as acetylcholinesterase and butyrylcholinesterase inhibitors.
Granica S; Kiss AK; Jarończyk M; Maurin JK; Mazurek AP; Czarnocki Z
Arch Pharm (Weinheim); 2013 Nov; 346(11):775-82. PubMed ID: 24123207
[TBL] [Abstract][Full Text] [Related]
19. Acetylcholinesterase inhibition in Alzheimer's Disease.
Ibach B; Haen E
Curr Pharm Des; 2004; 10(3):231-51. PubMed ID: 14754384
[TBL] [Abstract][Full Text] [Related]
20. Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase.
Perola E; Cellai L; Lamba D; Filocamo L; Brufani M
Biochim Biophys Acta; 1997 Nov; 1343(1):41-50. PubMed ID: 9428657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
